Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 465

Sort by

Sort Order Select

Journal Articles

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Mario Scarpa, PhD, Prerna Singh, MS, Shivani Kapoor, MS, Jonelle K. Lee, MS, Sandrine Niyongere, MD, Goutham Narla, MD PhD, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2019) 134 (Supplement_1): 1276.

https://doi.org/10.1182/blood-2019-129011

Published: 2019

Journal Articles

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Hudan Liu, PhD, Jue Jiang, PhD, Jingchao Wang, PhD, Ming Yue, PhD, Hui Feng, MD PhD, Guoliang Qing, PhD

Blood (2019) 134 (Supplement_1): 732.

https://doi.org/10.1182/blood-2019-130112

Published: 2019

Journal Articles

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Yuqi Zhu, Ye Yang, PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3102.

https://doi.org/10.1182/blood-2019-123815

Published: 2019

Journal Articles

Glia Maturation Factor-γ Regulates Autophagy in Murine Macrophages

Wulin Aerbajinai, MD PhD, Jianqiong Zhu, MD, Chutima Kumkhaek, PhD, Kyung Chin, Griffin Rodgers, MD

Blood (2019) 134 (Supplement_1): 2318.

https://doi.org/10.1182/blood-2019-130318

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

Laury Poulain, PhD, Adrien Grenier, MD PhD, Johanna Mondesir, MD, Arnaud Jacquel, PhD, Claudie Bosc, Lucille Stuani, PhD, Rudy Birsen, MD, Sarah Mouche, Justine Decroocq, MD, Fetta Mazed, PhD, Benoit Viollet, PhD, Patrick Auberger, PhD, Pierre Sujobert, MD PhD, Didier Bouscary, MD PhD, Jean-Emmanuel Sarry, PhD, Jerome Tamburini, MD PhD

Blood (2019) 134 (Supplement_1): 2552.

https://doi.org/10.1182/blood-2019-123364

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Chandrika Gowda, MBBS, Chunhua Song, MD, Sadie Steffens, PhD, Yali Ding, PhD, Bo Zhang, Feng Yue, PhD, Soumya Iyer, PhD, Pavan kumar Dhanyamraju, PhD, Jonathon Payne, Morgann Reed, BS, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2522.

https://doi.org/10.1182/blood-2019-131200

Published: 2019

Journal Articles

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Sara Gandolfi, MD, Michal Sheffer, PhD, Olli Dufva, Khalid Saeed, Emily Lowry, Olga Dashevsky, PhD, Ryosuke Shirasaki, MD PhD, Ricardo De Matos Simoes, PhD, Jennifer Roth, Rizwan Romee, MD PhD, Satu Mustjoki, MD PhD, Constantine S. Mitsiades, MD PhD

Blood (2019) 134 (Supplement_1): 620.

https://doi.org/10.1182/blood-2019-130793

Published: 2019

Journal Articles

Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV)-Positive B-Cell, T-Cell, and Hodgkin Lymphoma: Interim Safety and Efficacy Results from a Phase 1b/2a Study

Blood (2019) 134 (Supplement_1): 465.

https://doi.org/10.1182/blood-2019-132004

Published: 2019

Journal Articles

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Tara L. Lin, MD, Pamela S. Becker, MD PhD, Prapti A. Patel, MD, Eunice S. Wang, MD, Alexander I. Spira, PhD MD FACP, Michaela L. Tsai, MD, Maya Ridinger, Peter J Croucher, PhD, Mark Erlander, PhD, Sandra L Silberman, MD PhD

Blood (2019) 134 (Supplement_1): 230.

https://doi.org/10.1182/blood-2019-126262

Published: 2019

Journal Articles

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia Cells

Sylwia Flis, Ewelina Bratek, Tomasz Chojnacki, Marlena Piskorek, Tomasz Skorski, MD PhD

Blood (2019) 134 (Supplement_1): 4143.

https://doi.org/10.1182/blood-2019-129093

Published: 2019

Journal Articles

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Jihad Aljabban, MMSc, BA, David Chen, BS, Francesca Cottini, MD, Saad Syed, BS, Nabeal Aljabban, BS, Sharjeel Syed, BS, Tiffany Hughes, PhD, David Feldman, BS, Dexter Hadley, MD PhD, Don M. Benson, Jr., MD PhD

Blood (2019) 134 (Supplement_1): 4395.

https://doi.org/10.1182/blood-2019-129699

Published: 2019

Journal Articles

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Fred Csibi, Nan Ji, PhD, Bin Yang, Karen Yuan, Michele Mayo, Haojing Rong, PhD, Scott Rusin, Kirti Sharma, Christine Loh, PhD, Henry Li, PhD, Sharon Townson, Jesse Chen, PhD, Hari Kamadurai, PhD, Duncan Walker, PhD, Jared Gollob, PhD MD, Nello Mainolfi, PhD

Blood (2019) 134 (Supplement_1): 3803.

https://doi.org/10.1182/blood-2019-128981

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Shan Lin, Yusuke Tarumoto, Jinhua Wang, PhD, Joseph Milazzo, Yali Xu, Nathanael Gray, Christopher Vakoc, Kimberly Stegmaier, MD

Blood (2019) 134 (Supplement_1): 3941.

https://doi.org/10.1182/blood-2019-125278

Published: 2019

Journal Articles

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

Jonathan Kopel, BS, Sriman Swarup, MDMBBS, Anita Sultan, MD, Lukman Tijani, MD, Ei Moe Phyu, MD, Myint Aung Win, MDMBBS, Thura Win Htut, MBBS, MRCP, Ye Aung, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Donald P. Quick, MD, Nicholas D'Cunha, MD, Kyaw Zin Thein, MDMBBS

Blood (2019) 134 (Supplement_1): 5489.

https://doi.org/10.1182/blood-2019-123179

Published: 2019

Journal Articles

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Blood (2019) 134 (Supplement_1): 4224.

https://doi.org/10.1182/blood-2019-124458

Published: 2019

Journal Articles

Targeting Polo-like Kinase 4 for Therapeutic Benefit in the Patients with Diffuse Large B-Cell Lymphoma

Yi Zhao, MM, Yang Han, MM, Juan Yang, MM, Shunfeng Hu, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2568.

https://doi.org/10.1182/blood-2019-129548

Published: 2019

Journal Articles

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Anders Berglund, Paula S. Oliveira, Allison Distler, Praneeth Reddy Sudalagunta, PhD, Timothy Jacobson, Jamie Teer, PhD, Eric A. Welsh, PhD, Hongyue Dai, PhD, John M. Koomen, PhD, Alugubelli Raghunandan Reddy, Gabriel De Avila, Alexandre Tungesvik, MD, William Roush, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, John Cleveland, PhD

Blood (2019) 134 (Supplement_1): 5537.

https://doi.org/10.1182/blood-2019-130830

Published: 2019

Journal Articles

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcarcel, Richard C. Woodman, MD, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Matthew Parris, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4249.

https://doi.org/10.1182/blood-2019-132127

Published: 2019

NARROW

PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation

Direct Phosphorylation and Stabilization of MYC By Aurora B Kinase Promotes T Cell Leukemogenesis

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Glia Maturation Factor-γ Regulates Autophagy in Murine Macrophages

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

PKR-like Endoplasmic Reticulum Kinase Mediates Apoptosis Induced By Pharmacological AMP-Activated Protein Kinase Activation in Acute Myeloid Leukemia

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Heterogeneity of Molecular Mechanisms Determining Blood Cancer Cell Lines Resistance to Natural Killer Cells in the Context of Tumor-Stromal Interactions: Insights from Studies of Pooled "DNA-Barcoded" Cell Line Panels

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinases Exerts Synergistic Effect Against Chronic Myeloid Leukemia Cells

Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data

Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Targeting Salt-Inducible Kinase 3 As a Therapeutic Approach for Acute Myeloid Leukemia

Risk of Serious Adverse Events, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Treated with Idelalisib

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Targeting Polo-like Kinase 4 for Therapeutic Benefit in the Patients with Diffuse Large B-Cell Lymphoma

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only